EverSource Wealth Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

EverSource Wealth Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-42	Closed	-$2.47K	–	3028
2023 Q4	$2.47K	Hold	42	–	–	﹤0.01%	2114
2023 Q3	$1.83K	Buy	+42	New	+$1.5K	﹤0.01%	2031
2022 Q2	–	Sell	-38	Closed	-$3K	–	1928
2022 Q1	$3K	Hold	38	–	–	﹤0.01%	1472
2021 Q4	$6K	Buy	+38	New	+$5.9K	﹤0.01%	1217

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EverSource Wealth Advisors's MRTX Position: Q1 2024 in Review

EverSource Wealth Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 42 shares — an estimated $2.47K sold.

EverSource Wealth Advisors first reported a position in MRTX in Q4 2021 and held it in 4 quarters. The position peaked at $6K in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

EverSource Wealth Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
EverSource Wealth Advisors sold 42 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.47K.
EverSource Wealth Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
EverSource Wealth Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2021.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on EverSource Wealth Advisors's 13F filing for Q1 2024, filed 13 May 2024.